ClinicalTrials.gg
TerminatedNCT01363986Updated Aug 11, 2014Results posted

A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

A Phase 2 interventional study of trastuzumab [Herceptin] in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 16 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was prematurely terminated due to difficulties experienced in recruiting patients in a reasonable timeframe.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
347th of 366
3 · median 61
Started
2011
with 18 others
Phase 2
239 of 374
44 open now
Registered
170th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 347th largest by enrollment of the 366 interventional ones that give a count, is one of 19 that started in 2011, is one of 239 in phase 2, and was the 170th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer. The patients will receive Herceptin 4 mg/kg (loading dose) followed by 2 mg/kg for a maximum of 18 weekly cycles. The anticipated time on study treatment is 18 weeks.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/=18 years of age
  • Diagnosis of breast carcinoma with overexpression
  • At least one measurable
  • Patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option
  • Performance status (WHO) \</=2
  • >/=3 months

Exclusion criteria

Exclusion Criteria:

  • Presence of neoplastic meningitis
  • Any prior radiotherapy to the brain
  • Patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option
  • Previous neoplasms, other than breast carcinoma, within 5 years since enrolment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Trastuzumab Monotherapy

    Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.

    Drug: trastuzumab [Herceptin]

Interventions

  • Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Brain Objective Response According to Response Evaluation Criteria In Solid Tumors (RECIST) Criteria at Cycle 7

    Brain objective response was defined as either a complete response (CR) or partial response (PR), provided that there was no increase in steroid requirements or worsening of neurological signs and symptoms. CR was defined as the disappearance of all central nervous system (CNS) lesions. PR was defined as a greater than or equal to (≥) 30 percent (%) reduction in the volumetric sum of all measurable CNS lesions.

    Time frame: Baseline and Cycle 7 (Week 7, approximately 5 weeks after completion of whole brain radiotherapy [WBRT])

Secondary outcomes

  1. Number of Participants With Brain Objective Response According to RECIST Criteria at Cycle 15

    Brain objective response was defined as either a CR or PR, provided that there was no increase in steroid requirements or worsening of neurological signs and symptoms. CR was defined as the disappearance of all CNS lesions. PR was defined as ≥30% reduction in the volumetric sum of all measurable CNS lesions.

    Time frame: Baseline and Cycle 15 (Week 15, approximately 13 weeks after completion of WBRT)

  2. Number of Participants With Brain Objective Response Defined According to RECIST Criteria at the Final Visit

    Brain objective response was defined as either a CR or PR), provided that there was no increase in steroid requirements, or worsening of neurological signs and symptoms. CR was defined as the disappearance of all CNS lesions. PR was defined as ≥30% reduction in the volumetric sum of all measurable CNS lesions.

    Time frame: BL and 4 weeks after Cycle 15 (Week 15, approximately 13 weeks after completion of WBRT) or the last dose of study treatment

  3. Overall Survival

    The number of participants surviving at the final visit.

    Time frame: Baseline, weekly for 3 weeks (pre-WBRT phase), Cycles 1 through 15 (treatment phase Weeks 1 through 15), and 4 weeks after Cycle 15 (Week 15) or the last dose of study treatment

  4. Brain Progression-Free Survival (B-PFS)

    B-PFS was defined as the time from the date of first study drug assumption and the date of documented evidence of brain progression (defined as appearance of new brain metastases or progression of pre-existing lesions) or death for brain progression, whichever came first. Progression in other metastatic sites, deaths not due to brain-progression and withdrawals due to adverse events were to be considered as competing risk.

    Time frame: Baseline, weekly for 3 weeks (pre-WBRT phase), Cycles 1 through 15 (treatment phase Weeks 1 through 15), and 4 weeks after Cycle 15 (Week 15) or the last dose of study treatment

07

Results

Posted Aug 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Monotherapy
Started3
Completed2
Not completed1
Withdrew: Disease progression1

Outcome measures

PrimaryNumber of Participants With Brain Objective Response According to Response Evaluation Criteria In Solid Tumors (RECIST) Criteria at Cycle 7

Brain objective response was defined as either a complete response (CR) or partial response (PR), provided that there was no increase in steroid requirements or worsening of neurological signs and symptoms. CR was defined as the disappearance of all central nervous system (CNS) lesions. PR was defined as a greater than or equal to (≥) 30 percent (%) reduction in the volumetric sum of all measurable CNS lesions.

Time frame:
Baseline and Cycle 7 (Week 7, approximately 5 weeks after completion of whole brain radiotherapy [WBRT])
Reported as:
Number · participants
Number of Participants With Brain Objective Response According to Response Evaluation Criteria In Solid Tumors (RECIST) Criteria at Cycle 7
participantsTrastuzumab Monotherapy
Number of Participants With Brain Objective Response According to Response Evaluation Criteria In Solid Tumors (RECIST) Criteria at Cycle 72
SecondaryNumber of Participants With Brain Objective Response According to RECIST Criteria at Cycle 15

Brain objective response was defined as either a CR or PR, provided that there was no increase in steroid requirements or worsening of neurological signs and symptoms. CR was defined as the disappearance of all CNS lesions. PR was defined as ≥30% reduction in the volumetric sum of all measurable CNS lesions.

Time frame:
Baseline and Cycle 15 (Week 15, approximately 13 weeks after completion of WBRT)
Reported as:
Number · participants
Number of Participants With Brain Objective Response According to RECIST Criteria at Cycle 15
participantsTrastuzumab Monotherapy
Number of Participants With Brain Objective Response According to RECIST Criteria at Cycle 150
SecondaryNumber of Participants With Brain Objective Response Defined According to RECIST Criteria at the Final Visit

Brain objective response was defined as either a CR or PR), provided that there was no increase in steroid requirements, or worsening of neurological signs and symptoms. CR was defined as the disappearance of all CNS lesions. PR was defined as ≥30% reduction in the volumetric sum of all measurable CNS lesions.

Time frame:
BL and 4 weeks after Cycle 15 (Week 15, approximately 13 weeks after completion of WBRT) or the last dose of study treatment
Reported as:
Number · participant
Number of Participants With Brain Objective Response Defined According to RECIST Criteria at the Final Visit
participantTrastuzumab Monotherapy
Number of Participants With Brain Objective Response Defined According to RECIST Criteria at the Final Visit1
SecondaryOverall Survival

The number of participants surviving at the final visit.

Time frame:
Baseline, weekly for 3 weeks (pre-WBRT phase), Cycles 1 through 15 (treatment phase Weeks 1 through 15), and 4 weeks after Cycle 15 (Week 15) or the last dose of study treatment
Reported as:
Number · participant
Overall Survival
participantTrastuzumab Monotherapy
Overall Survival1
SecondaryBrain Progression-Free Survival (B-PFS)

B-PFS was defined as the time from the date of first study drug assumption and the date of documented evidence of brain progression (defined as appearance of new brain metastases or progression of pre-existing lesions) or death for brain progression, whichever came first. Progression in other metastatic sites, deaths not due to brain-progression and withdrawals due to adverse events were to be considered as competing risk.

Time frame:
Baseline, weekly for 3 weeks (pre-WBRT phase), Cycles 1 through 15 (treatment phase Weeks 1 through 15), and 4 weeks after Cycle 15 (Week 15) or the last dose of study treatment

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were reported from randomization up through 28 days after the final study drug treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Monotherapy—0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTrastuzumab Monotherapy
AstheniaGeneral disorders3/3
HeadacheGeneral disorders2/3
NauseaGastrointestinal disorders1/3
DyspnoeaRespiratory, thoracic and mediastinal disorders1/3
PyrexiaGeneral disorders1/3
EpilepsyNervous system disorders1/3
Musculoskeletal painMusculoskeletal and connective tissue disorders1/3
Device-related infectionInfections and infestations1/3
DiarrhoeaGastrointestinal disorders1/3
HyperglycaemiaMetabolism and nutrition disorders1/3

Baseline characteristics

Intent to treat (ITT) population included all consented participants who received study treatment.

Age, Continuous
Age, Continuous(years)Trastuzumab Monotherapy
Median60 (37 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Monotherapy
Female3
Male0
08

Study locations

16 sites
  • Ancona, Italy
  • Brindisi, 72100, Italy
  • Candiolo, 10060, Italy
  • Firenze, 50134, Italy
  • Latina, 04100, Italy
  • Lecce, 73100, Italy
  • Meldola, 47014, Italy
  • Parma, 43100, Italy
  • Ravenna, 48100, Italy
  • Roma, 00168, Italy
  • Rozzano, 20089, Italy
  • San Giovanni Rotondo, 71013, Italy
  • Saronno, 21047, Italy
  • Sassari, 07100, Italy
  • Torino, 10126, Italy
  • Viterbo, 01100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 2, 2011
Start
Sep 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Aug 11, 2014
Last update
Aug 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01363986
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 2, 2011
Start date
Sep 2011
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 11, 2014
Last update
Aug 11, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion